Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Astellas Pharma and Daiichi Sankyo Form Compound Library Sharing Partnership

Published: Saturday, March 22, 2014
Last Updated: Saturday, March 22, 2014
Bookmark and Share
Both Companies will exchange approximately 400,000 selected compounds.

Astellas Pharma Inc. and Daiichi Sankyo Company, Limited have announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds.

The collaboration enables each party to promote innovative new medicine research and development. This is the first time that a compound library partnership of this scale has been formed in Japan.

Astellas and Daiichi Sankyo have compound libraries that are the basis for their drug discovery research, and through High Throughput Screening (HTS), the companies can quickly and effectively search for potentially beneficial compounds to develop innovative new drugs.

Extensive, diverse, and high-quality compound libraries, such as the joint Astellas/Daiichi Sankyo libraries, are crucial to successful drug discovery.

This partnership will give each company access to qualitatively different compound libraries-which have been developed based on the targeting disease strategies of each company-allowing both companies to implement broader HTS to generate innovative new drugs.

Under this partnership, Astellas and Daiichi Sankyo will exchange approximately 400,000 selected compounds, including a significant number of proprietary synthetic compounds, from their respective compound libraries. Beginning April 1, 2014, for a period of three years, both Astellas and Daiichi Sankyo will be able to implement broad HTS using the shared compounds without restrictions on targeted disease areas. In line with the partnership, each company will disclose sufficient information to allow the receiving company to implement HTS independently.

If, as a result of HTS, the receiving company identifies a candidate compound to be used for a new drug discovery, the receiving company may carry out development and commercialization of the innovative new drug with an indication for any human diseases from the compound pursuant to the terms of agreement.

Astellas and Daiichi Sankyo have each set forth a corporate philosophy to contribute to the health of people around the world. Through this partnership, both companies aim to effectively utilize each other’s assets and knowledge beyond the framework of one pharmaceutical company, and accelerate open innovation while taking advantage of their own internal strengths to provide innovative new drugs.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Astellas Pharma and BioFocus Sign Target Discovery Agreement
Collaboration agreement with Astellas focused on discovering novel targets in the field of CNS disorders.
Friday, May 13, 2011
Astellas Pharma Europe Appoints Ken Jones as President and CEO
Ken Jones succeeds Mr Masao Yoshida, who has been appointed as President and CEO of Astellas Pharma US, Inc.
Tuesday, April 19, 2011
Astellas Begins Screening Another Target From Metabolex Gene Database
Initiation of screening against unique target triggers milestone payment to Metabolex.
Monday, September 18, 2006
Scientific News
Promising Blood Test Fails to Yield Clues About Best Strategies for Bladder Cancer Treatment
Penn Medicine research challenges previous findings on utility of neutrophil-to-lymphocyte ratio as a biomarker.
Influential Cancer Researcher Receives Agilent Thought Leader Award
Biologist Scott Lowe receives award in recognition for his contributions to cancer biology.
Startup Seeks More Precise Prostate Cancer Screening
Gregor Diagnostics aims to bring a non-invasive prostate cancer screening test to the market.
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
Preventing "Friendly Fire" in the Pancreas
Researchers inhibit process that leads to the body attacking its own insulin-producing cells.
Drug Target for Triple-Negative Breast Cancer Found
A team of researchers led by UC San Francisco scientists has identified a new drug target for triple-negative breast cancer.
3D-Printed Heart-On-A-Chip with Integrated Sensors
Researchers have created the first 3D-printed organ-on-a-chip with integrated sensors, paving the way for more complex, customizable devices.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
First Entirely 3D-printed Organ-on-a-Chip with Integrated Sensors
New approach to manufacturing may allow researchers to rapidly design organs-on-chips that match the properties of a specific disease or individual patient's cells.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos